Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: June 23, 2026
AltaSeal
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): AltaScience
Inactive
Last updated: June 23, 2026
Nestorone Microarray Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Queens University Belfast, Population Council
Active
Last updated: June 23, 2026
Progestin Microarray Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Cardiff University, InnoCore Pharmaceuticals
Active
Last updated: June 22, 2026
Yaso Gel

PPCM Vaginal Gel

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Yaso Therapeutics, NIAID, Albert Einstein College of Medicine, University of Illinois at Chicago, University of Texas Medical Branch, NICHD, University of Pittsburgh, Magee-Womens Research Institute
Active
Last updated: June 22, 2026
Biodegradable Implant with [Poly(PDL-co-DO)] Co-Polymers

LNG Biodegradable Implant, Yale BDI

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Yale University
Inactive
Last updated: June 22, 2026
CatSper-Based Contraceptive Vaccine
  • User: Female/Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Rensselaer Polytechnic Institute, Yale University
Active
Last updated: June 22, 2026
Serine Protease Inhibitor

4-(2-Aminoethyl)Benzenesulfonyl Fluoride (AEBSF), CDD-3290

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Washington State University, Baylor College of Medicine, University of Missouri
Active
Last updated: June 5, 2026
Plan A Male Contraceptive System

Vasalgel

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Vas Deferens
  • Intended Duration: Long-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Parsemus Foundation, NEXT Life Sciences
Active
Last updated: June 5, 2026
NLS-133 Non-Hormonal Oral Contraceptive
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): NEXT Life Sciences
Active
Last updated: June 5, 2026
Silodosin
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): TSS Shripad Hegde Kadave Institute of Medical Sciences, Benha University, Recep Tayyip Erdogan University